reports
- David Carlson
- David Nierengarten
- Dennis Pak
- Martin Fan
- Dave Nicoski
- Ross LaDuke
Vermilion Compass: Weekly Equity Strategy
Mixed Signals, Reasons for Caution The S&P 500 uptrend remains intact, and the same can be said for the QQQ's. Despite a positive view of these two metrics, the aspect of of failed U.S. dollar breakdown coupled with the reversal. of the 10-year yields higher does give us pause. The S&P 500 breadth is showing signs of breadth divergence. 1.) The U.S. dollar has staged a false breakdown and is now on the cusp of a reversal. A decisive close through last Friday's close of 104.89 could yet negate t...
TJX TJX COMPANIES INC
SXT SENSIENT TECHNOLOGIES CORPORATION
MATX MATSON INC.
IFF INTERNATIONAL FLAVORS & FRAGRANCES INC.
ASC ARDMORE SHIPPING
SBL SAFE BULKERS INC.
GNK GENCO SHIPPING & TRADING LTD.
LCM COSTAMARE INC.
ROST ROSINTER RESTAURANTS HOLDING ORD SHS
SBLK STAR BULK CARRIERS CORP.
KEX KIRBY CORPORATION
NMM NAVIOS MARITIME PARTNERS
DAC DANAOS
HSHP HIMALAYA SHIPPING LTD.
ESEA EUROSEAS LTD
- Wedbush Research
DPZ DOMINO'S PIZZA INC.
WFC WELLS FARGO & COMPANY
WDC WESTERN DIGITAL CORPORATION
UMH UMH PROPERTIES INC.
TTWO TAKE-TWO INTERACTIVE SOFTWARE INC.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
SBRA SABRA HEALTH CARE REIT INC.
RHP RYMAN HOSPITALITY PROPERTIES INC.
PSTG PURE STORAGE INC. CLASS A
PEB PEBBLEBROOK HOTEL TRUST
OHI OMEGA HEALTHCARE INVESTORS INC.
OFC CORPORATE OFFICE PROPERTIES TRUST
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
NHI NATIONAL HEALTH INVESTORS INC.
MXL MAXLINEAR INC
MU MICRON TECHNOLOGY INC.
KURA KURA ONCOLOGY INC.
INTC INTEL CORPORATION
GOOGL ALPHABET INC. CLASS A
GLPI GAMING AND LEISURE PROPERTIES INC.
FB FACEBOOK INC. CLASS A
EQR EQUITY RESIDENTIAL
EGP EASTGROUP PROPERTIES INC.
CPT CAMDEN PROPERTY TRUST
AXTI AXT INC.
HST HOST HOTELS & RESORTS INC.
7974 NINTENDO CO. LTD.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
EA ELECTRONIC ARTS INC.
PK PARK HOTELS & RESORTS INC.
VTR VENTAS INC.
VICI VICI PROPERTIES INC
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
AVGO BROADCOM INC.
SAFE SAFEHOLD INC.
PEAK HEALTHPEAK PROPERTIES INC.
SMCI SUPER MICRO COMPUTER
VOR INC.
AIRC VOR BIOPHARMA
SNOW APARTMENT INCOME REIT
CGEM SNOWFLAKE INC. CLASS A
FHTX CULLINAN ONCOLOGY INC
STX FOGHORN THERAPEUTICS
TCRX SEAGATE TECHNOLOGY HLDGS PLC
GFS TSCAN THERAPEUTICS INC
HR GLOBALFOUNDRIES INC
DNTH HEALTHCARE TRUST OF AMERICA INC.
DIANTHUS THERAPEUTICS INC
- David Carlson
- David Nierengarten
- Dennis Pak
- Martin Fan
- Ritika Das
- Robert Driscoll
- Sam Ravina
- Wedbush Research
XNCR XENCOR INC.
XENE XENON PHARMACEUTICALS INC
VYGR VOYAGER THERAPEUTICS INC.
SGMO SANGAMO THERAPEUTICS INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
PCRX PACIRA BIOSCIENCES INC.
NVCR NOVOCURE LTD.
NBIX NEUROCRINE BIOSCIENCES INC.
KURA KURA ONCOLOGY INC.
KPTI KARYOPHARM THERAPEUTICS
GERN GERON CORP.
FATE FATE THERAPEUTICS INC
CTMX CYTOMX THERAPEUTICS INC.
CMRX CHIMERIX INC
BPMC BLUEPRINT MEDICINES CORP.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
ARDX ARDELYX INC
APLE APPLE HOSPITALITY REIT INC
FRX_CN FENNEC PHARMACEUTICALS
UTHR UNITED THERAPEUTICS CORPORATION
CLSD CLEARSIDE BIOMEDICAL INC
ALBO ALBIREO PHARMA
CVNA CARVANA CO. CLASS A
ANAB ANAPTYSBIO INC.
KALA KALA PHARMACEUTICALS INC.
ARGX ARGENX ADS
MRSN MERSANA THERAPEUTICS
GTHX G1 THERAPEUTICS
ALPN ALPINE IMMUNE SCIENCES
APLS APELLIS PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
SURF SURFACE ONCOLOGY
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
LQDA LIQUIDIA CORPORATION
REPL REPLIMUNE GROUP
ARVN ARVINAS HOLDING
YMAB Y-MABS THERAPEUTICS
STRO SUTRO BIOPHARMA
BCEL ATRECA
STOK STOKE THERAPEUTICS
IGMS IGM BIOSCIENCES
SWTX SPRINGWORKS THERAPEUTICS
AQST AQUESTIVE THERAPEUTICS
IDYA IDEAYA BIOSCIENCES
PASG PASSAGE BIO
BDTX BLACK DIAMOND THERAPEUTICS
ACET ADICET BIO INC
ITOS ITEOS THERAPEUTICS
ORIC ORIC PHARMACEUTICALS
ZNTL ZENTALIS PHARMACEUTICALS
BEAM BEAM THERAPEUTICS
PRAX PRAXIS PRECISION MEDICINES
COGT COGENT BIOSCIENCES INC
TVTX TRAVERE THERAPEUTICS INC
VRDN VIRIDIAN THERAPEUTICS INC
IMNM IMMUNOME
NUVB NUVATION BIO INC (A)
CGEM CULLINAN ONCOLOGY INC
DAWN DAY ONE BIOPHARMACEUTICALS INC
ELEV ELEVATION ONCOLOGY
OMGA OMEGA THERAPEUTICS
LBPH LONGBOARD PHARMACEUTICALS
THRX THESEUS PHARMACEUTICALS
IKNA INC.
TCRX IKENA ONCOLOGY INC
DSGN TSCAN THERAPEUTICS INC
ATXS DESIGN THERAPEUTICS INC
AVTE ASTRIA THERAPEUTICS INC
GMTX AEROVATE THERAPEUTICS INC
S GEMINI THERAPEUTICS INC
RLYB SENTINELONE INC
KRTX RALLYBIO CORP
FUSN KARUNA THERAPEUTICS INC
VIGL FUSION PHARMACEUTICALS INC
PEPG VIGIL NEUROSCIENCE INC
EWTX PEPGEN INC
NUVL EDGEWISE THERAPEUTICS INC
NUVALENT INC
- Ritika Das
- Robert Driscoll
- Sam Ravina
Cullinan Therapeutics Announces Positive Initial Data from Pivotal Pha...
Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib Objective response rate of 39% with manageable safety profile in patients with non-small cell lung cancer (NSCLC) harboring EGFR Exon 20 insertion mutations treated with zipalertinib who had progressed after prior amivantamab treatment CAMBRIDGE, Mass., June 01, 2024 (GLOBE NEWSWIRE) -- . (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced positive initial data in patients receiving zipalertinib after prior treat...
HCI Group Completes its 2024 – 2025 Catastrophe Reinsurance Programs
HCI Group Completes its 2024 – 2025 Catastrophe Reinsurance Programs TAMPA, Fla., May 30, 2024 (GLOBE NEWSWIRE) -- (NYSE: HCI), a holding company with operations in homeowners insurance, information technology services, real estate, and reinsurance, announced today that it has completed its catastrophe reinsurance programs for the 2024-2025 treaty year, which runs from June 1, 2024 through May 31, 2025. “We appreciate the broad support we received from our valued reinsurance partners,” said Paresh Patel, HCI’s chairman and chief executive officer. “HCI continues to maintain a conservati...
Cannae Holdings Inc: 1 director
A director at Cannae Holdings Inc sold 25,752 shares at 19.380USD and the significance rating of the trade was 60/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cle...
- David Carlson
- David Nierengarten
- Dennis Pak
- Laura Chico
- Martin Fan
- Ritika Das
- Robert Driscoll
- Sam Ravina
NTLA INTELLIA THERAPEUTICS INC.
RCUS ARCUS BIOSCIENCES
SRRK SCHOLAR ROCK HOLDING CORPORATION
REPL REPLIMUNE GROUP
YMAB Y-MABS THERAPEUTICS
SWTX SPRINGWORKS THERAPEUTICS
BDTX BLACK DIAMOND THERAPEUTICS
ORIC ORIC PHARMACEUTICALS
COGT COGENT BIOSCIENCES INC
NUVB NUVATION BIO INC (A)
CGEM CULLINAN ONCOLOGY INC
IKNA IKENA ONCOLOGY INC
TCRX TSCAN THERAPEUTICS INC
HOWL WEREWOLF THERAPEUTICS INC
CMPX COMPASS THERAPEUTICS
Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th ...
Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit CAMBRIDGE, Mass., May 24, 2024 (GLOBE NEWSWIRE) -- . (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced that Nadim Ahmed, Chief Executive Officer and Jeffrey Jones, MD, MBA, Chief Medical Officer, will participate in a fireside chat at the TD Cowen 5th Annual Oncology Innovation Summit: Insights for ASCO & EHA, being held virtually on May 28 and 29, 2024. The fireside chat is scheduled for Wednesday, May 29, 2024 at 1...
- Wedbush Research
XENE XENON PHARMACEUTICALS INC
V VISA INC. CLASS A
TSCO TRACTOR SUPPLY COMPANY
TRIP TRIPADVISOR INC.
SAGE SAGE THERAPEUTICS INC.
NVCR NOVOCURE LTD.
NBIX NEUROCRINE BIOSCIENCES INC.
HURN HURON CONSULTING GROUP INC.
GOOGL ALPHABET INC. CLASS A
FL FOOT LOCKER INC.
FATE FATE THERAPEUTICS INC
EXPE EXPEDIA GROUP INC.
DECK DECKERS OUTDOOR CORPORATION
BPMC BLUEPRINT MEDICINES CORP.
BIIB BIOGEN INC.
AZO AUTOZONE INC.
ARDX ARDELYX INC
AAP ADVANCE AUTO PARTS INC.
KO COCA-COLA COMPANY
TSC TRISTATE CAPITAL HOLDINGS INC
ORLY O'REILLY AUTOMOTIVE INC.
PK PARK HOTELS & RESORTS INC.
CVCO CAVCO INDUSTRIES INC.
MRSN MERSANA THERAPEUTICS
GTHX G1 THERAPEUTICS
GM GENERAL MOTORS COMPANY
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
BKNG BOOKING HOLDINGS INC.
RCUS ARCUS BIOSCIENCES
SRRK SCHOLAR ROCK HOLDING CORPORATION
REPL REPLIMUNE GROUP
ARVN ARVINAS HOLDING
YMAB Y-MABS THERAPEUTICS
STRO SUTRO BIOPHARMA
LYFT LYFT
UBER UBER TECHNOLOGIES INC.
CHWY CHEWY INC. CLASS A
STOK STOKE THERAPEUTICS
SWTX SPRINGWORKS THERAPEUTICS
LC LENDINGCLUB CORP
IDYA IDEAYA BIOSCIENCES
GDYN GRID DYNAMICS
BDTX BLACK DIAMOND THERAPEUTICS
ITOS ITEOS THERAPEUTICS
ORIC ORIC PHARMACEUTICALS
ZNTL ZENTALIS PHARMACEUTICALS
BEAM BEAM THERAPEUTICS
COGT COGENT BIOSCIENCES INC
DASH DOORDASH
ABNB AIRBNB INC. CLASS A
IMNM IMMUNOME
VOR VOR BIOPHARMA
WOOF PETCO HEALTH AND WELLNESS
NUVB NUVATION BIO INC (A)
CGEM CULLINAN ONCOLOGY INC
DAWN DAY ONE BIOPHARMACEUTICALS INC
ELEV ELEVATION ONCOLOGY
LBPH LONGBOARD PHARMACEUTICALS
FOUR SHIFT4 PAYMENTS
IKNA IKENA ONCOLOGY INC
TCRX TSCAN THERAPEUTICS INC
HOWL WEREWOLF THERAPEUTICS INC
FLYW FLYWIRE CORP
GLUE MONTE ROSA THERAPEUTICS INC
CMPX COMPASS THERAPEUTICS
GMTX GEMINI THERAPEUTICS INC
CINT CI&T INC
YOU CLEAR SECURE INC
TOST TOAST INC
HR HEALTHCARE TRUST OF AMERICA INC.
EWTX EDGEWISE THERAPEUTICS INC
NUVL NUVALENT INC
EMBRAC B EMBRACER GROUP AB
- David Carlson
- David Nierengarten
- Dennis Pak
- Martin Fan
- Ritika Das
- Robert Driscoll
- Sam Ravina
NVCR NOVOCURE LTD.
FL FOOT LOCKER INC.
FATE FATE THERAPEUTICS INC
BPMC BLUEPRINT MEDICINES CORP.
TSC TRISTATE CAPITAL HOLDINGS INC
PK PARK HOTELS & RESORTS INC.
MRSN MERSANA THERAPEUTICS
GTHX G1 THERAPEUTICS
GM GENERAL MOTORS COMPANY
RCUS ARCUS BIOSCIENCES
SRRK SCHOLAR ROCK HOLDING CORPORATION
REPL REPLIMUNE GROUP
ARVN ARVINAS HOLDING
YMAB Y-MABS THERAPEUTICS
STRO SUTRO BIOPHARMA
SWTX SPRINGWORKS THERAPEUTICS
LC LENDINGCLUB CORP
IDYA IDEAYA BIOSCIENCES
BDTX BLACK DIAMOND THERAPEUTICS
ITOS ITEOS THERAPEUTICS
ORIC ORIC PHARMACEUTICALS
ZNTL ZENTALIS PHARMACEUTICALS
BEAM BEAM THERAPEUTICS
COGT COGENT BIOSCIENCES INC
IMNM IMMUNOME
VOR VOR BIOPHARMA
NUVB NUVATION BIO INC (A)
CGEM CULLINAN ONCOLOGY INC
DAWN DAY ONE BIOPHARMACEUTICALS INC
ELEV ELEVATION ONCOLOGY
IKNA IKENA ONCOLOGY INC
TCRX TSCAN THERAPEUTICS INC
HOWL WEREWOLF THERAPEUTICS INC
GLUE MONTE ROSA THERAPEUTICS INC
CMPX COMPASS THERAPEUTICS
GMTX GEMINI THERAPEUTICS INC
HR HEALTHCARE TRUST OF AMERICA INC.
NUVL NUVALENT INC
Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-...
Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024 Preliminary data from CLN-619 in combination with checkpoint inhibitor pembrolizumab show objective responses in patients with tumor types that are typically unresponsive to pembrolizumab, such as non-small cell lung cancer (NSCLC) with oncogenic mutations Longer term follow-up for patients treated with CLN-619 monotherapy demonstrates durable clinical benefit across multiple tumor types CLN-619 continues to demonstrate...
- Martin Fan
- Ritika Das
- Robert Driscoll
- Sam Ravina
- Wedbush Research
QRVO QORVO INC.
KMX CARMAX INC.
WDC WESTERN DIGITAL CORPORATION
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
SBUX STARBUCKS CORPORATION
QCOM QUALCOMM INC
PSTG PURE STORAGE INC. CLASS A
ORCL ORACLE CORPORATION
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
INTC INTEL CORPORATION
GOOGL ALPHABET INC. CLASS A
AXTI AXT INC.
SKY SKYLINE CHAMPION CORPORATION
SWKS SKYWORKS SOLUTIONS INC.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
SLM SLM CORP
ALPN ALPINE IMMUNE SCIENCES
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
DT DYNATRACE INC.
SMCI SUPER MICRO COMPUTER
CGEM INC.
STX CULLINAN ONCOLOGY INC
TMC SEAGATE TECHNOLOGY HLDGS PLC
GFS THE METALS COMPANY INC
CRLBF GLOBALFOUNDRIES INC
BROS CRESCO LABS INC.
DUTCH BROS INC
Cullinan Therapeutics Provides Corporate Update and Reports First Quar...
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results Combination and monotherapy solid tumor dose escalation data for CLN-619 to be presented in a poster session at ASCO 2024 Annual Meeting CLN-978 development to focus exclusively on autoimmune diseases, starting with systemic lupus erythematosus (SLE) as the first indication Cash and investments of $434.8 million as of March 31, 2024, plus gross proceeds of $280 million from April private placement extends cash runway into 2028 Company appoints David Meek to its Board of Directors CAMBRIDGE, ...
Cannae Holdings, Inc. Announces Quarterly Cash Dividend of $0.12
LAS VEGAS--(BUSINESS WIRE)-- Cannae Holdings, Inc. (NYSE: CNNE) (“Cannae” or the “Company”) today announced that its Board of Directors has declared a quarterly cash dividend of $0.12 per share. The dividend will be payable June 28, 2024, to shareholders of record as of June 14, 2024. About Cannae Holdings, Inc. We primarily acquire interests in operating companies and are actively engaged in managing and operating a core group of those companies. We believe that our long-term ownership and active involvement in the management and operations of companies helps maximize the value of those b...
Cannae Holdings, Inc. Announces First Quarter 2024 Financial Results
LAS VEGAS--(BUSINESS WIRE)-- Cannae Holdings, Inc. (NYSE: CNNE) (“Cannae” or the “Company”) has released its first quarter 2024 financial results by posting them to its website. Please visit the Cannae website at to view the first quarter 2024 financial results, which are included in its Letter to Shareholders. Conference Call As previously announced, Cannae will host a conference call, today, May 9, 2024 at 5:00pm (Eastern Time), to discuss its first quarter 2024 results. The conference call can be accessed by dialing 1-844-826-3035 (domestic) or 1-412-317-5195 (international) and asking...
HCI Group Reports First Quarter 2024 Results
HCI Group Reports First Quarter 2024 Results First Quarter Pre-Tax Income of $77.4 millionFirst Quarter Diluted EPS of $3.81First Quarter Gross Loss Ratio of 31.1% TAMPA, Fla., May 08, 2024 (GLOBE NEWSWIRE) -- HCI Group, Inc. (NYSE:HCI), a holding company with operations in homeowners insurance, information technology services, real estate, and reinsurance, reported pre-tax income of $77.4 million and net income of $57.0 million, or $3.81 diluted earnings per share, in the first quarter of 2024, compared with net income of $17.8 million, or $1.54 diluted earnings per share, in the first ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.